JP2021518408A5 - - Google Patents

Info

Publication number
JP2021518408A5
JP2021518408A5 JP2020550758A JP2020550758A JP2021518408A5 JP 2021518408 A5 JP2021518408 A5 JP 2021518408A5 JP 2020550758 A JP2020550758 A JP 2020550758A JP 2020550758 A JP2020550758 A JP 2020550758A JP 2021518408 A5 JP2021518408 A5 JP 2021518408A5
Authority
JP
Japan
Prior art keywords
cancer
item
combination according
nucleic acid
acid encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020550758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518408A (ja
JP7849143B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022985 external-priority patent/WO2020036635A2/en
Publication of JP2021518408A publication Critical patent/JP2021518408A/ja
Publication of JP2021518408A5 publication Critical patent/JP2021518408A5/ja
Priority to JP2024060696A priority Critical patent/JP2024074924A/ja
Application granted granted Critical
Publication of JP7849143B2 publication Critical patent/JP7849143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550758A 2018-03-19 2019-03-19 癌治療のための、癌抑制遺伝子治療法及びcd122/cd132アゴニストを含む、方法及び組成物 Active JP7849143B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024060696A JP2024074924A (ja) 2018-03-19 2024-04-04 癌治療のための、癌抑制遺伝子治療法及びcd122/cd132アゴニストを含む、方法及び組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862645022P 2018-03-19 2018-03-19
US62/645,022 2018-03-19
US201962803887P 2019-02-11 2019-02-11
US62/803,887 2019-02-11
PCT/US2019/022985 WO2020036635A2 (en) 2018-03-19 2019-03-19 Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024060696A Division JP2024074924A (ja) 2018-03-19 2024-04-04 癌治療のための、癌抑制遺伝子治療法及びcd122/cd132アゴニストを含む、方法及び組成物

Publications (3)

Publication Number Publication Date
JP2021518408A JP2021518408A (ja) 2021-08-02
JP2021518408A5 true JP2021518408A5 (enExample) 2022-03-22
JP7849143B2 JP7849143B2 (ja) 2026-04-21

Family

ID=69525688

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550758A Active JP7849143B2 (ja) 2018-03-19 2019-03-19 癌治療のための、癌抑制遺伝子治療法及びcd122/cd132アゴニストを含む、方法及び組成物
JP2024060696A Pending JP2024074924A (ja) 2018-03-19 2024-04-04 癌治療のための、癌抑制遺伝子治療法及びcd122/cd132アゴニストを含む、方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024060696A Pending JP2024074924A (ja) 2018-03-19 2024-04-04 癌治療のための、癌抑制遺伝子治療法及びcd122/cd132アゴニストを含む、方法及び組成物

Country Status (8)

Country Link
US (2) US12454561B2 (enExample)
EP (1) EP3768698B1 (enExample)
JP (2) JP7849143B2 (enExample)
KR (1) KR20200135986A (enExample)
CN (1) CN112020510B (enExample)
AU (1) AU2019322487B2 (enExample)
CA (1) CA3094329A1 (enExample)
WO (1) WO2020036635A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230016178A (ko) * 2020-04-15 2023-02-01 엘커메스 파마 아일랜드 리미티드 혈관신생 억제제와 조합된 면역자극제
EP4178586A4 (en) * 2020-07-09 2024-10-09 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Compositions and methods for inhibiting ythdf1
WO2022140776A1 (en) * 2020-12-21 2022-06-30 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy for the inhibition of pathogens
CN113368246B (zh) * 2021-05-12 2023-05-26 中山大学 一种增效的抗肿瘤药物
IL310201A (en) * 2021-07-19 2024-03-01 Regeneron Pharma Combination of inhibitor-control inhibitor and oncolytic virus for cancer treatment
CN115287299B (zh) * 2021-12-29 2023-12-29 浙江理工大学 一种重组溶瘤痘苗病毒的构建方法及其应用
EP4486457A1 (en) 2022-03-04 2025-01-08 Rejuveron Senescence Therapeutics AG Anti pd-l2 antibody
WO2024196963A2 (en) * 2023-03-21 2024-09-26 The Regents Of The University Of California Compositions and methods for genome editing
CN116789828B (zh) * 2023-05-31 2023-11-17 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种抗cd132的单克隆抗体及其应用
CN117700554B (zh) * 2023-08-03 2024-07-12 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种抗人源cd132的单克隆抗体及其应用
WO2025226592A1 (en) * 2024-04-22 2025-10-30 The Johns Hopkins University Cytotoxic synergy of crispr-cas9 with dna damage repair inhibitors
CN118697886A (zh) * 2024-05-31 2024-09-27 中南大学湘雅三医院 一种药物组合物及其应用

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4835251A (en) 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
DE4204650C1 (enExample) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
ATE398679T1 (de) 1992-07-07 2008-07-15 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
JP2952041B2 (ja) 1992-07-27 1999-09-20 パイオニア ハイ−ブレッド インターナショナル,インコーポレイテッド 培養ダイズ細胞のagrobacterium媒介形質転換の改良法
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0665852A1 (en) 1993-07-09 1995-08-09 Amgen Boulder Inc. Recombinant ctla4 polypeptides and methods for making the same
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
CA2174354C (en) 1993-10-27 2011-03-29 Paul B. Fisher Compositions of melanoma differentiation associated gene-7 (mda-7) in cancer diagnosis and treatment
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5710137A (en) 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US6413544B1 (en) 1996-08-19 2002-07-02 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
US5736167A (en) 1997-02-27 1998-04-07 Chang; Hui Hwa Mold device for making safety shoe
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド 免疫療法のctla−4結合ペプチド
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US7589069B1 (en) 1999-07-12 2009-09-15 Saint Louis University Replication-competent anti-cancer vectors
CA2379171A1 (en) 1999-07-15 2001-01-25 Introgen Therapeutics, Inc. Methods for treatment of hyperproliferative diseases using human mda-7
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
GB2375113B (en) 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
CA2511625A1 (en) 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
KR100523028B1 (ko) 2003-02-27 2005-10-20 윤채옥 개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터
HRP20120845T1 (hr) 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
HRP20170342T1 (hr) 2003-07-24 2017-05-19 Innate Pharma S.A. Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice
US20070281041A1 (en) 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
CN101103043A (zh) 2005-01-06 2008-01-09 诺和诺德公司 Kir结合剂和使用其的方法
US20070066552A1 (en) * 2005-01-21 2007-03-22 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
KR100747646B1 (ko) 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
US20070160578A1 (en) 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
CN105037549B (zh) 2007-01-11 2018-09-28 诺和诺德公司 抗-kir抗体、制剂及其应用
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
NZ599338A (en) 2007-06-27 2013-11-29 Marinepolymer Tech Inc Complexes of il-15 and il-15ralpha and uses thereof
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AU2009206225B2 (en) 2008-01-25 2015-04-23 Multivir Inc. p53 biomarkers
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN101658670A (zh) 2008-08-25 2010-03-03 中国疾病预防控制中心性病艾滋病预防控制中心 基于n1l和b8r基因缺失的痘苗病毒载体的艾滋病疫苗
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Pd−1アンタゴニストおよび感染性疾患を処置するための方法
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
HUE026386T2 (en) 2009-03-02 2016-06-28 Univ California Tumor-selective adenovirus e1a and e1b mutants
GR1006941B (el) 2009-06-01 2010-08-27 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Πεπτιδικη συνθεση (peptide synthesis)
BR112012007875A2 (pt) 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
HUE030100T2 (en) 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2011278931A1 (en) 2010-07-16 2013-03-07 Epeius Biotechnologies Corporation Targeted nanoparticles for cancer and other disorders
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2643350A4 (en) 2010-11-22 2015-01-07 Innate Pharma Sa TREATMENTS WITH NK CELL MODULATION AND METHOD FOR THE TREATMENT OF HEMATOLOGICAL MALIGNOMES
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2522726A1 (en) 2011-05-12 2012-11-14 Fundació Privada Centre de Regulació Genòmica (CRG) Zinc finger nucleases for p53 editing
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
WO2013112942A1 (en) 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
US20150072988A1 (en) * 2012-03-30 2015-03-12 The Johns Hopkins University Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
KR20210008155A (ko) 2012-08-30 2021-01-20 암젠 인크 단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
HK1211027A1 (en) 2012-10-16 2016-05-13 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
CN103110939A (zh) 2012-10-23 2013-05-22 郑州大学 诱导肿瘤特异性免疫的疫苗及其应用
WO2014100014A1 (en) 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
WO2014164942A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Dual mek/pi3k inhibitors and therapeutic methods using the same
WO2014150056A1 (en) 2013-03-15 2014-09-25 Numbergun Llc Improvements for base64 encoding and decoding
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
AU2014296887A1 (en) 2013-08-02 2016-01-28 Aduro Biotech Holdings, Europe B.V. Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
RS65104B1 (sr) 2013-08-22 2024-02-29 Univ Pittsburgh Commonwealth Sys Higher Education Onkolitičke imunoterapije
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
WO2015082376A2 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
GB201405834D0 (en) 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
DK3166973T3 (da) 2014-07-10 2020-04-06 Univ Zuerich Immunstimulerende monoklonale antistoffer mod human interleukin-2
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
RU2696312C2 (ru) 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
WO2017079746A2 (en) * 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
KR20180117227A (ko) * 2016-03-24 2018-10-26 난트셀, 인크. 네오에피토프 제시를 위한 시퀀스들 및 시퀀스 배열들
CN111201035A (zh) * 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法

Similar Documents

Publication Publication Date Title
JP2021518408A5 (enExample)
JP2018532810A5 (enExample)
KR102333658B1 (ko) 비-소세포 폐암을 치료하기 위한 항-b7-h1 및 항-ctla-4 항체
JP2020510624A5 (enExample)
Economopoulou et al. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
JP2024095709A5 (enExample)
EP3768698B1 (en) Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
US20200009203A1 (en) Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
JP2021527694A5 (enExample)
CA3011004A1 (en) Oncolytic virus comprising a fusogenic protein-encoding gene and immune stimulatory protein-encoding gene
JP2020503871A5 (enExample)
Shi et al. Mechanisms of resistance to checkpoint blockade therapy
Zhang et al. Advances in immunotherapies for gliomas
WO2019183117A1 (en) Methods and compositions comprising genetically engineered vaccines for the treatment and prevention of cancer
CA3224890A1 (en) Lag-3 antagonist therapy for hematological cancer
Suresh et al. The emerging role of immunotherapy in head and neck squamous cell cancer
Salkeni et al. Resistance to immunotherapy: mechanisms and means for overcoming
KR20220054826A (ko) 항암바이러스, 면역관문억제제 및 히드록시유레아를 유효성분으로 포함하는 암 치료용 약학 조성물
TW202304512A (zh) 雙特異性t細胞銜接體之給藥
Shah et al. Advances in biological treatment of melanoma
HK40042181B (zh) 包含用於治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
HK40046148A (en) Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
HK40046148B (en) Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
HK40042181A (en) Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
HK1235023A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer